TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01114568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow
Study: NCT03577600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QMRT with the Cytotron®
Description: Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
Study: NCT02100982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized Care
Description: Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.

Intervention type: OTHER
Group type: OTHER
Intervention: Care As Usual
Description: Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
Study: NCT00896168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
Study: NCT05200195

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
Study: NCT03008148

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siroquine
Description: 1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed.
Study: NCT04988854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression video
Description: Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression video
Description: Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression video
Description: Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
Study: NCT03466333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate
Description: Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
Study: NCT01354158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
Study: NCT04295733

Intervention type: BIOLOGICAL
Intervention: 4CMenB (Bexsero®) vaccine
Description: Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart

Intervention type: BIOLOGICAL
Intervention: 4CMenB (Bexsero®) vaccine
Description: Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart

Intervention type: BIOLOGICAL
Intervention: 4CMenB (Bexsero®) vaccine
Description: Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
Study: NCT04609579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX281
Description: SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
Study: NCT00440648

Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer carbonate, sevelamer hydrochloride
Description: Starting dose individualized for each patient and fixed daily dose throughout both treatment periods

Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer hydrochloride, sevelamer carbonate
Description: Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
Study: NCT00605800

Intervention type: OTHER
Intervention: blood drawn
Description: Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).

Intervention type: OTHER
Intervention: blood drawn
Description: At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
Study: NCT03464227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0107
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use
Study: NCT02107118

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARM 1: AdMSC: adipose stem cells
Description: Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ARM 2: Placebo
Description: Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
Study: NCT01725646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor®
Description: Subjects in 4 g and 2 g Omacor® will take this drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor®
Description: Subjects in 4 g and 2 g Omacor® will take this drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in placebo group will take this drug
Study: NCT01206738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive communication
Description: The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action plan
Description: This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
Study: NCT02823665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
Study: NCT01575951

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-DCE
Description: The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week.
Study: NCT02391012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial l transplantation
Description: infusion of preparation of fecal preparation from a healthy donor to a colitis patient
Study: NCT04291183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: horticultural therapy
Description: Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
Study: NCT00735813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Description: When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: When not in use the childrens tunneled central venous catheters are locked with heparin
Study: NCT00767455

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HP828-101
Description: 21 day patches
Study: NCT02914613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution
Study: NCT01511978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous 3,4-DAP
Description: Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taper 3,4-DAP to Placebo
Description: Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
Study: NCT01278004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT00703157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Patients undergoing left atrial circumferential pulmonary vein ostia ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Ablation
Description: patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
Study: NCT02195869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT04319263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction regimen of intravesical BCG
Description: intravesical instillation of 6 weekly doses of BCG
Study: NCT04189315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Description: Asfotase alfa is administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Description: Asfotase alfa is administered subcutaneously.
Study: NCT01206738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General intervention
Description: No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
Study: NCT02725632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: The patients on CPAP treatment will be followed-up for 1 month.
Study: NCT03857659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POC-US)
Description: POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
Study: NCT00083382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
Study: NCT04689620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: treating the venous ulcer with laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: treating the venous ulcer with laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: treating the venous ulcer with laser
Study: NCT04105166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L301
Description: Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
Study: NCT03857659

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine antenatal care
Description: Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Formal ultrasound
Description: Formal growth ultrasound performed between 36-38.6 weeks by RDMS.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Formal ultrasound
Description: Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
Study: NCT03084055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMotion
Description: eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
Study: NCT03989466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO
Study: NCT02353546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Study: NCT00749073

Intervention type: DEVICE
Group type: OTHER
Intervention: Minimally Invasive Lumbar Decompression (MILD™)
Description: The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
Study: NCT01288482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse II breath-actuated nebulizer
Description: The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: English-Wright continuous-mode nebulizer
Description: The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
Study: NCT05486195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule
Study: NCT00726752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.